-
Cancer detection using SPR: Announcing our partnership with INOVIQ
The SubB2M™-based SPR test will detect for pan-cancer biomarker Neu5Gc in blood samples on Alto™, and will initially be used as a cancer risk assessment test. We’re excited to announce our partn...
-
What’s in store for 2022? Announcing our $20M Series A Extension
Equipping biologics researchers with disruptive tools in the era of proteomics Ryan Denomme, Co-founder and CEO At Nicoya, we build proteomics tools to provide researchers with powerful insights while...
-
Nicoya Launches Alto™, the World’s First Digital Benchtop SPR System, to Accelerate Drug Discovery
Groundbreaking new SPR system uses digital microfluidics technology and flexible 16-channel design to reduce the time and cost of drug discovery KITCHENER, ON – January 23, 2020 – Nicoya, a leadin...